Compare BioNTech SE - ADR (BNTX) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Wynn Resorts, Limited — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Wynn Resorts, Limited trades at $103.25 (market cap $10.79B). The key difference: BioNTech SE - ADR is far larger — about 2.2× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays a 0.95% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | WYNN | |
|---|---|---|
Market Cap | $23.31B | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $133.34 |
52-Week Low | $83.89 | $94.37 |
Enterprise Value | $6.60B | $21.03B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Wynn Resorts (WYNN) trades at $103.51, up 0.99% today, showing steady recovery from pandemic lows. The stock maintains bullish technical signals with strong institutional support, though faces headwinds from high debt levels and margin pressure. Recent Q2 2026 earnings beat expectations with $1.24 EPS versus $0.99 estimate, driven by Macau strength, while Las Vegas operations show slower growth. Analyst consensus remains strongly bullish with 64% buy ratings and $133 price target, representing 28% upside potential.
Investment outlook balances growth potential against significant risks. The company's Macau recovery and UAE expansion provide growth catalysts, but high leverage ($10.5B debt) and rising capex for Wynn Al Marjan project create cash flow pressure. Current valuation at 25x P/E appears reasonable given recovery trajectory, but investors should monitor margin trends and capital expenditure discipline closely given the negative shareholder equity position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
